e-learning
resources
London 2016
Monday, 05.09.2016
IPF: from pathogenesis to treatment II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages
Katerina Antoniou (Heraklion, Crete, Greece), Eliza Tsitoura, Athol U. Wells, Chara Koutoulaki, Konstantinos Karagiannis, Ismini Lasithiotaki, Eirini Vasarmidi, Hiroe Sato, Demetrios A. Spandidos, Nikolaos M. Siafakas, Georgios Sourvinos, Katerina Antoniou
Source:
International Congress 2016 – IPF: from pathogenesis to treatment II
Session:
IPF: from pathogenesis to treatment II
Session type:
Poster Discussion
Number:
2094
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Katerina Antoniou (Heraklion, Crete, Greece), Eliza Tsitoura, Athol U. Wells, Chara Koutoulaki, Konstantinos Karagiannis, Ismini Lasithiotaki, Eirini Vasarmidi, Hiroe Sato, Demetrios A. Spandidos, Nikolaos M. Siafakas, Georgios Sourvinos, Katerina Antoniou. MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages. Eur Respir J 2016; 48: Suppl. 60, 2094
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
The RANKL-OPG balance in pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
CFTR-dependent deficiency in alternatively-activated macrophages in cystic fibrosis
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016
Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP)
Source: International Congress 2014 – ILDs 2
Year: 2014
Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Characterization of M1 and M2 macrophages in human lung tissue
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013
Alveolar type II cells transplantation in pulmonary fibrosis: Effect on the lung macrophage activation
Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Year: 2013
Impaired HGF-production by alveolar macrophages is a feature of diabetic pneumonia
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
Functional phenotype of immune response and alveolar macrophages phenotype in pulmonary sarcoidosis
Source: International Congress 2014 – New insights into monocyte and macrophage biology
Year: 2014
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Oxidative stress drives defective efferocytosis in COPD M2-like macrophages
Source: International Congress 2014 – New insights into monocyte and macrophage biology
Year: 2014
Induced pluripotent stem cells conditioned media (iPS-cm) modulates macrophage phenotype in the fibrotic lung
Source: International Congress 2014 – Lung cell biology in injury and repair
Year: 2014
Neutrophil chemotaxis and adhesion in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 108s
Year: 2001
Elevated GM-CSF in COPD may drive defective macrophage phenotype
Source: International Congress 2014 – New insights into monocyte and macrophage biology
Year: 2014
Pulmonary alveolar proteinosis: iPS derived macrophages as in-vitro disease model and potential source for novel gene and cell therapies
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
M2 polarized alveolar macrophages in pulmonary fibrosis
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Clinical and functional features in idiopathic pulmonary fibrosis (IPF) with and without haemosiderin-laden alveolar macrophages on BALF
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Impaired monocyte chemotaxis in COPD
Source: International Congress 2015 – Mucosal immunology: what’s new in 2015
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept